Cited by 174Autophagy in Disease and TherapyGlioma Diagnosis and TreatmentCell death mechanisms and regulation

Inhibition of autophagy at a late stage enhances imatinib‐induced cytotoxicity in human malignant glioma cells

Open access
Shingu, Takashi, Fujiwara, Keishi, Bögler, Oliver, Akiyama, Yasuhiko, Moritake, Kouzo, Shinojima, Naoki, Tamada, Yutaka, Yokoyama, Tomohisa +1 more·2009·International Journal of Cancer

Abstract

Malignant gliomas are common primary tumors of the central nervous system. The prognosis of patients with malignant glioma is poor in spite of current intensive therapy and thus novel therapeutic modalities are necessary. Imatinib mesylate, a tyrosine kinase inhibitor, is effective in the therapy of tumors including leukemias but not as a monotherapy for malignant glioma. Recently, it is thought that the adequate modulation of autophagy can enhance efficacy of anticancer therapy. The outcome of autophagy manipulation, however, seems to depend on the autophagy initiator, the combined stimuli, the extent of cellular damage and the type of cells, and it is not yet fully understood how we should modulate autophagy to augment efficacy of each anticancer therapy. In this study, we examined the effect of imatinib with or without different types of autophagy inhibitors on human malignant glioma cells. Imatinib inhibited the viability of U87‐MG and U373‐MG cells in a dose dependent manner and caused nonapoptotic autophagic cell death. Suppression of imatinib‐induced autophagy by 3‐methyladenine or small interfering RNA against Atg5, which inhibit autophagy at an early stage, attenuated the imatinib‐induced cytotoxicity. In contrast, inhibition of autophagy at a late stage by bafilomycin A1 or RTA 203 enhanced imatinib‐induced cytotoxicity through the induction of apoptosis following mitochondrial disruption. Our findings suggest that therapeutic efficiency of imatinib for malignant glioma may be augmented by inhibition of autophagy at a late stage, and that appropriate modulation of autophagy may sensitize tumor cells to anticancer therapy. © 2008 Wiley‐Liss, Inc.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.24030

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Amenta JS, Sargus MJ, Baccino FM. Effect of microtubular or transla- tional inhibitors on general cell protein degradation. Biochem J 1977; 168:223-27.

Cited by

Sorted by citations

Authors
Shingu, T., Fujiwara, K., Bögler, O., Akiyama, Y., Moritake, K., Shinojima, N., Tamada, Y., Yokoyama, T., & Kondo, S.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • Shimane University (JP)
Corresponding author
Shingu, Takashi
Venue
International Journal of Cancer
Publisher
Wiley
Published
2008-12
Volume
124
Issue
5
Pages
1060-1071
ISSN
  • 0020-7136 (ISSN-L)
  • 1097-0215
OpenAlex
W2022040605
Cited by
174
References
47
Citations by year
2026: 1 · 2025: 2 · 2024: 3 · 2023: 5 · 2022: 5 · 2021: 7 · 2020: 9 · 2019: 12 · 2018: 9 · 2017: 3 · 2016: 14 · 2015: 14 · 2014: 20 · 2013: 22 · 2012: 15
FWCI
8.16
Type
journal article
Language
en
Open access
Locations
  • International Journal of Cancer (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Autophagy in Disease and Therapy
  • Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
Keywords
high-grade glioma, imatinib, autophagy inhibition, autophagic cell death, apoptosis, bafilomycin A1, 3-methyladenine, ATG5, U87 cells, U373 cells, tyrosine kinase inhibitors, combination therapy, mitochondrial disruption
MeSH terms
Imatinib Mesylate, Autophagy-Related Protein 5, Adenine, Antineoplastic Agents, Autophagy, Benzamides, Brain Neoplasms, Cisplatin, Glioma, Humans, Microtubule-Associated Proteins, Piperazines, Pyrimidines, Paclitaxel, Macrolides, Bridged Bicyclo Compounds, Heterocyclic, MAP Kinase Signaling System, Cell Line, Tumor, Extracellular Signal-Regulated MAP Kinases, Membrane Potential, Mitochondrial

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review